Incidence and treatment outcome of aplastic anemia in Taiwan—real-world data from single-institute experience and a nationwide population-based database

Research output: Contribution to journalArticle

Abstract

Aplastic anemia (AA) is a rare disease characterized by pancytopenia and bone marrow failure. The incidence of AA tends to be higher in Asia than in the West, but real-world data about AA in Asia remain limited. We aimed to describe the basic data, treatment, and outcome of AA patients from our institute and evaluate the incidence of AA in Taiwan with a nationwide population-based cohort from National Health Insurance Research Database (NHIRD). We identified patients older than 2 years with AA in the Registry of Catastrophic Illness of NHIRD between 2001 and 2010 and excluded patients with any diagnosis suggestive of congenital or secondary bone marrow failure. With a total of 1270 patients, the overall incidence was 5.67 per million people per year, and there was a biphasic age distribution of incidence rate, highest in ≥ 70 years (19.83 per million people per year) and another peak at age 2–9 years (5.26 per million people per year). Overall, the 5-year survival was 60.0%. Hematopoietic stem cell transplantation (HSCT) and anti-thymocyte globulin-based immunosuppressive therapy (IST) were the major first-line treatments in patients younger than 40 years and were linked with good survival. In contrast, the majority of patients older than 60 years were treated with androgen, and the survival was poor. In multivariate analysis, “severe AA,” “very severe AA,” and “treatment other than HSCT, IST, or androgen” were independent risk factors for inferior survival. In conclusion, the incidence of AA in Taiwan is consistent with nearby Asian countries and is higher than in the West. Advanced age is associated with higher incidence and poorer outcome.

Original languageEnglish
Pages (from-to)29-39
Number of pages11
JournalAnnals of Hematology
Volume98
Issue number1
DOIs
Publication statusPublished - 2019 Jan 30

Fingerprint

Aplastic Anemia
Databases
Incidence
Population
Survival
Hematopoietic Stem Cell Transplantation
National Health Programs
Immunosuppressive Agents
Taiwan
Androgens
Catastrophic Illness
Bone Marrow
Pancytopenia
Antilymphocyte Serum
Age Distribution
Therapeutics
Rare Diseases
Research
Registries
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{a7c8befd3b054f3baf87968f6e86cf9c,
title = "Incidence and treatment outcome of aplastic anemia in Taiwan—real-world data from single-institute experience and a nationwide population-based database",
abstract = "Aplastic anemia (AA) is a rare disease characterized by pancytopenia and bone marrow failure. The incidence of AA tends to be higher in Asia than in the West, but real-world data about AA in Asia remain limited. We aimed to describe the basic data, treatment, and outcome of AA patients from our institute and evaluate the incidence of AA in Taiwan with a nationwide population-based cohort from National Health Insurance Research Database (NHIRD). We identified patients older than 2 years with AA in the Registry of Catastrophic Illness of NHIRD between 2001 and 2010 and excluded patients with any diagnosis suggestive of congenital or secondary bone marrow failure. With a total of 1270 patients, the overall incidence was 5.67 per million people per year, and there was a biphasic age distribution of incidence rate, highest in ≥ 70 years (19.83 per million people per year) and another peak at age 2–9 years (5.26 per million people per year). Overall, the 5-year survival was 60.0{\%}. Hematopoietic stem cell transplantation (HSCT) and anti-thymocyte globulin-based immunosuppressive therapy (IST) were the major first-line treatments in patients younger than 40 years and were linked with good survival. In contrast, the majority of patients older than 60 years were treated with androgen, and the survival was poor. In multivariate analysis, “severe AA,” “very severe AA,” and “treatment other than HSCT, IST, or androgen” were independent risk factors for inferior survival. In conclusion, the incidence of AA in Taiwan is consistent with nearby Asian countries and is higher than in the West. Advanced age is associated with higher incidence and poorer outcome.",
author = "Sin-Syue Li and Ya-Ting Hsu and Chen Chang and Lee, {Shang Chi} and Yen, {Chi Chieh} and Chao-Neng Cheng and Chien-Hsu Chen and Sheng-Hsiang Lin and Kung-Chao Chang and Tsai-Yun Chen",
year = "2019",
month = "1",
day = "30",
doi = "10.1007/s00277-018-3486-3",
language = "English",
volume = "98",
pages = "29--39",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Incidence and treatment outcome of aplastic anemia in Taiwan—real-world data from single-institute experience and a nationwide population-based database

AU - Li, Sin-Syue

AU - Hsu, Ya-Ting

AU - Chang, Chen

AU - Lee, Shang Chi

AU - Yen, Chi Chieh

AU - Cheng, Chao-Neng

AU - Chen, Chien-Hsu

AU - Lin, Sheng-Hsiang

AU - Chang, Kung-Chao

AU - Chen, Tsai-Yun

PY - 2019/1/30

Y1 - 2019/1/30

N2 - Aplastic anemia (AA) is a rare disease characterized by pancytopenia and bone marrow failure. The incidence of AA tends to be higher in Asia than in the West, but real-world data about AA in Asia remain limited. We aimed to describe the basic data, treatment, and outcome of AA patients from our institute and evaluate the incidence of AA in Taiwan with a nationwide population-based cohort from National Health Insurance Research Database (NHIRD). We identified patients older than 2 years with AA in the Registry of Catastrophic Illness of NHIRD between 2001 and 2010 and excluded patients with any diagnosis suggestive of congenital or secondary bone marrow failure. With a total of 1270 patients, the overall incidence was 5.67 per million people per year, and there was a biphasic age distribution of incidence rate, highest in ≥ 70 years (19.83 per million people per year) and another peak at age 2–9 years (5.26 per million people per year). Overall, the 5-year survival was 60.0%. Hematopoietic stem cell transplantation (HSCT) and anti-thymocyte globulin-based immunosuppressive therapy (IST) were the major first-line treatments in patients younger than 40 years and were linked with good survival. In contrast, the majority of patients older than 60 years were treated with androgen, and the survival was poor. In multivariate analysis, “severe AA,” “very severe AA,” and “treatment other than HSCT, IST, or androgen” were independent risk factors for inferior survival. In conclusion, the incidence of AA in Taiwan is consistent with nearby Asian countries and is higher than in the West. Advanced age is associated with higher incidence and poorer outcome.

AB - Aplastic anemia (AA) is a rare disease characterized by pancytopenia and bone marrow failure. The incidence of AA tends to be higher in Asia than in the West, but real-world data about AA in Asia remain limited. We aimed to describe the basic data, treatment, and outcome of AA patients from our institute and evaluate the incidence of AA in Taiwan with a nationwide population-based cohort from National Health Insurance Research Database (NHIRD). We identified patients older than 2 years with AA in the Registry of Catastrophic Illness of NHIRD between 2001 and 2010 and excluded patients with any diagnosis suggestive of congenital or secondary bone marrow failure. With a total of 1270 patients, the overall incidence was 5.67 per million people per year, and there was a biphasic age distribution of incidence rate, highest in ≥ 70 years (19.83 per million people per year) and another peak at age 2–9 years (5.26 per million people per year). Overall, the 5-year survival was 60.0%. Hematopoietic stem cell transplantation (HSCT) and anti-thymocyte globulin-based immunosuppressive therapy (IST) were the major first-line treatments in patients younger than 40 years and were linked with good survival. In contrast, the majority of patients older than 60 years were treated with androgen, and the survival was poor. In multivariate analysis, “severe AA,” “very severe AA,” and “treatment other than HSCT, IST, or androgen” were independent risk factors for inferior survival. In conclusion, the incidence of AA in Taiwan is consistent with nearby Asian countries and is higher than in the West. Advanced age is associated with higher incidence and poorer outcome.

UR - http://www.scopus.com/inward/record.url?scp=85053421139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053421139&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3486-3

DO - 10.1007/s00277-018-3486-3

M3 - Article

VL - 98

SP - 29

EP - 39

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -